Results 221 to 230 of about 33,284,612 (360)

The dawn of a new era: can machine learning and large language models reshape QSP modeling? [PDF]

J Pharmacokinet Pharmacodyn
Androulakis IP, Cucurull-Sanchez L, Kondic A, Mehta K, Pichardo C, Pryor M, Renardy M.   +6 more
europepmc   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Overexpression of Decorin Optimizes the Treatment Efficacy of Umbilical Cord Mesenchymal Stem Cells in Bleomycin-Induced Pulmonary Fibrosis in Rats. [PDF]

Stem Cells Int
Zhi Y, Shu M, Tang P, Li Y, Guo M, Deng J, Mo H, Wu M, Liu B, Mai Y, Ling J, Zhao X, Zhang X, Zuo W.   +13 more
europepmc   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Finishing and inspection of model surfaces for boundary-Layer-Transition tests [PDF]

, 1959
M. E. Wilkins, John F. Darsow
openalex   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model-Commentary on Sheiner et al. [PDF]

Clin Pharmacol Ther
Karlsson MO.
europepmc   +1 more source

Beam Stacking Experiments in an Electron Model FFAG Accelerator

, 1957
K. M. Terwilliger, Lyndon Jones, C. H. Pruett   +2 more
openalex   +2 more sources

Exactly renormalizable model in quantum field theory III. Renormalization in the case of two V-particles [PDF]

, 1959
Th.W. Ruijgrok
openalex   +1 more source

Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?

Molecular Oncology, EarlyView.
 
Chen‐xi Li, Zhong‐cheng Gong
wiley   +1 more source